Business, energy, technology, markets and global industry news from Business News Today

Phase I clinical trial

PharmaDeviceNews Phase I clinical trial
Representative image: Harbour BioMed’s FDA-cleared HBM7004 IND highlights the growing race to develop B7-H4xCD3 bispecific antibodies for advanced solid tumors, as biotech firms test whether next-generation immunotherapies can improve cancer treatment options beyond conventional approaches.
Pharma & Biotech

HBM7004 FDA clearance gives Harbour BioMed a fresh solid tumor immunotherapy test

Solid tumor T-cell engagers still face safety limits. Harbour BioMed’s HBM7004 now tests whether B7-H4 can widen that window.

Read More
Pharma & Biotech

Meiji Seika Pharma initiates ME3241 Phase I study, inverting checkpoint blockade logic for autoimmune therapy

Meiji Seika Pharma initiates Phase I of ME3241, a PD-1 agonist antibody for autoimmune disease in Australia. Read the clinical analysis.

Read More
Pharma & Biotech

FDA IND clearance propels ViroMissile’s IDOV-Immune into major U.S. cancer centers

ViroMissile expands its IDOV-Immune Phase I trial to U.S. sites after FDA IND clearance. Discover what this means for systemic oncolytic therapy.

Read More